Fintel reports that on January 10, 2025, BTIG initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation.

Energy & Infrastructure Analyst Lewis and Fixed Income Strategist Malley discuss bitcoin mining trends and themes across the capital ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price target of ...

BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...

The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...

BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they could rally this year.

BTIG analyst Gray Powell keeps a Buy rating and $30 price target on SentinelOne (S) but names the stock the firm’s Top Pick in Security & Infrastructure Software for 2025. The stock is ...

Palo Alto Networks (NASDAQ: PANW) investors just cannot catch a break. Over the past three days, this cybersecurity stock has been downgraded by three separate investment bank analysts, beginning with ...

BTIG analyst Julian Harrison initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $40 price target The firm sees the company’s AVTX-009 as having best-in-class features that ...

According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...